|2.||Neoplasm Metastasis (Metastasis)
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|4.||Lung Neoplasms (Lung Cancer)
|1.||Kiura, Katsuyuki: 24 articles (04/2014 - 01/2002)|
|2.||Tanimoto, Mitsune: 23 articles (01/2013 - 05/2002)|
|3.||Gandara, David R: 21 articles (07/2015 - 07/2003)|
|4.||Saijo, Nagahiro: 20 articles (07/2015 - 01/2002)|
|5.||Vokes, Everett E: 20 articles (07/2015 - 03/2004)|
|6.||Socinski, Mark A: 19 articles (02/2015 - 04/2003)|
|7.||Salgia, Ravi: 19 articles (03/2014 - 02/2002)|
|8.||Yamamoto, Nobuyuki: 18 articles (06/2015 - 07/2004)|
|9.||Tabata, Masahiro: 16 articles (10/2011 - 01/2002)|
|10.||Sone, Saburo: 15 articles (03/2013 - 02/2002)|
|1.||Etoposide (VP 16)FDA LinkGeneric
04/01/1992 - "The superior efficacy without increased toxicity of more prolonged schedules of etoposide administration has been demonstrated recently in patients with small cell lung cancer (SCLC). "
01/01/1987 - "We conclude that although etoposide improves the overall response rates in patients with small cell lung cancer, especially those with extensive disease, the addition of this drug does not lead to improved survival."
08/01/1989 - "It is concluded that etoposide in this dose regimen is an effective and well tolerated treatment for elderly patients with small cell lung cancer."
05/01/1988 - "Etoposide effective against small cell lung cancer."
01/01/1990 - "This case suggested that etoposide administered orally is useful in the treatment of small cell lung cancer especially in elderly patients with complications."
|2.||Cisplatin (Platino)FDA LinkGeneric
12/01/2014 - "We carried out a prospective phase II study of patients with limited stage small cell lung cancer (LS-SCLC) assigned to receive stereotactic body radiotherapy (SBRT) concurrently with cisplatin-based chemotherapeutic regimen with OS and PFS as the primary study endpoints. "
06/01/2013 - "In the present study, we aimed to determine whether the ERK1/2 and Akt pathways contribute to cisplatin resistance in human small cell lung cancer A549 cells. "
01/01/2010 - "The aim of this study is to explore the effect of Fas over-expression on cisplatin resistance of small cell lung cancer cells and its possible mechanisms. "
10/01/2008 - "A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer."
07/15/1990 - "A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance."
|3.||Carboplatin (JM8)FDA LinkGeneric
07/01/1988 - "Carboplatin was found to be effective for small-cell lung carcinoma. "
11/01/2001 - "days 6 to 15) administered every 3 weeks for 4 cycles and subsequent chest irradiation (50 Gy) + daily carboplatin (25 mg/m2) in the first-line treatment of adults affected by limited small cell lung cancer (SCLC). "
01/01/1998 - "The reduced toxicity and equivalent efficacy of carboplatin have resulted in the increased use of carboplatin-based regimens to treat small-cell lung cancer. "
08/01/2004 - "Reply ot the article "Continuously infused carboplatin used as radiosensitizer in locally unresectable no-small-cell lung cancer: a multicenter phase III study", by Groen et al. (Ann Oncol 2004; 15: 427-432)."
01/01/1998 - "Phase I and II trials of carboplatin as single-agent treatment for small-cell lung cancer resulted in overall response rates of approximately 60% for previously untreated patients and 17% for those who had received prior therapy. "
|4.||irinotecan (Camptosar)FDA LinkGeneric
09/01/2014 - "Low-dose irinotecan monotherapy for recurrent small cell lung cancer might be effective with favorable toxicity. "
03/01/1998 - "Irinotecan (CPT-11) is effective against small-cell lung cancer (SCLC) as monotherapy. "
07/01/2001 - "In single-agent phase II studies, irinotecan yielded response rates between 16% and 47% in patients with previously treated small-cell lung cancer. "
07/01/2000 - "Irinotecan in small-cell lung cancer--Japanese trials."
01/01/1994 - "In two phase II trials, CPT-11 achieved objective response rates of 37% and 47% for small cell lung cancer (SCLC). "
|5.||Topotecan (Hycamtin)FDA LinkGeneric
01/01/2010 - "Intravenous topotecan was at least as effective as CAV in the treatment of patients with recurrent small-cell lung cancer and resulted in improved quality-of-life with respect to several symptoms. "
06/01/2006 - "Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer."
12/01/2004 - "In patients with recurrent small-cell lung cancer, who frequently present with a compromised PS, the use of topotecan as a single agent led to an improvement in PS in approximately one third of these patients without excessive toxicities. "
01/01/2004 - "Topotecan in the first-line treatment of small cell lung cancer."
05/01/2002 - "[A case of recurrent small cell lung cancer with symptoms improved by nogitecan hydrochloride]."
|6.||Paclitaxel (Taxol)FDA LinkGeneric
11/01/2011 - "Single dose toxicity study of paclitaxel elastic liposomal and marketed formulation was carried out in dose range of 10, 20, 40, 80, 120, 160 and 200 mg/kg. Cytotoxicity of developed formulation was evaluated using small cell lung cancer cell line (A549). "
01/01/2006 - "The purpose of this study was to evaluate the efficacy and toxicity of single-agent paclitaxel given weekly to patients with relapsed and refractory small cell lung cancer (SCLC). "
01/01/2006 - "Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer."
03/01/2004 - "The H69-EPR, H69-CP, H69-VP and H69/R38 resistant sublines of the classic small cell lung cancer (SCLC) line have proven useful in studies of resistance and its circumvention with paclitaxel. "
01/01/2004 - "This study and others which have tested paclitaxel in small-cell lung cancer dampens enthusiasm for this agent in the primary management of LSCLC."
01/01/2015 - "Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials."
05/01/2015 - "Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer"."
05/01/2015 - "Second-line Treatment of Small Cell Lung Cancer: Is Platinum Sensitivity a Relevant Prognostic Factor?"
05/01/2015 - "Relevance of platinum sensitivity in patients with relapsed or refractory small-cell lung cancer."
01/01/2014 - "Targeted therapies in small cell lung cancer (SCLC) and thymic malignancies have not yielded meaningful clinical benefits, and platinum-based therapies remain the cornerstone of treating patients with advanced disease. "
|8.||Doxorubicin (Adriamycin)FDA LinkGeneric
05/08/1993 - "A study of cross-resistance pattern and expression of molecular markers of multidrug resistance in a human small-cell lung-cancer cell line selected with doxorubicin."
10/02/2014 - "HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer."
08/15/2006 - "In order to examine the protective role of alpha-class GST isozyme hGSTA1-1 against doxorubicin (DOX)-induced lipid peroxidation, cytotoxicity, and apoptosis, human small cell lung cancer (SCLC) H69 cells were stably transfected with hGSTA1. "
06/01/2003 - "A doxorubicin-resistant subline (U-1285dox(900)) was derived from the human small cell lung carcinoma cell line U-1285. "
01/01/1996 - "The anthracycline doxorubicin (DOX) is one of the most effective drugs for the treatment of small-cell lung cancer (SCLC), but its clinical application is limited by unspecific side-effects like cardiotoxicity. "
05/01/2009 - "In Japan, amrubicin is considered an effective agent for relapsed small cell lung cancer. "
03/01/2006 - "[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin]."
05/01/2014 - "Amrubicin (AMR), a new anthracycline agent, has shown promising results for advanced small-cell lung cancer (SCLC), although the efficacy of AMR alone against refractory relapsed SCLC is insufficient. "
08/01/2009 - "Amrubicin is a new anticancer drug that has been shown to exert efficacy against small cell lung cancer. "
05/01/2011 - "Recent reports have suggested the efficacy of amrubicin (AMR) for relapsed small-cell lung cancer (SCLC). "
|10.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/01/1994 - "In the late sixties the first randomized placebo controlled study with cyclophosphamide demonstrated improved survival in patients with extensive small cell lung cancer (SCLC). "
06/01/1995 - "After a remarkable improvement of the very poor prognosis of small cell lung cancer with very simple therapy such as iv and oral cyclophosphamide the role of oral therapy has become minimal. "
03/01/1991 - "Between March 1986 and May 1988, the Southwest Oncology Group enrolled 58 previously untreated patients with limited small-cell lung cancer on a treatment program that administered high-dose cyclophosphamide (150 mg/kg) as late intensification. "
10/01/1988 - "This paper investigates the ability of chemical compounds other than cyclophosphamide derivatives to eradicate small cell lung cancer (SCLC) in bone marrow. "
11/01/1979 - "VP-16-213 and cyclophosphamide in small cell lung cancer: a long-term followup report."
|1.||Drug Therapy (Chemotherapy)
02/05/2000 - "Small-cell lung cancer is highly responsive to chemotherapy, and recent advances in radiation therapy have improved the prospects for long survival. "
06/01/1996 - "The emergence of chemotherapy has dramatically improved both quality of life and survival in patients with small cell lung cancer (SCLC). "
07/03/2005 - "The authors examined whether the combined modality treatment in case of limited-stage small cell lung cancer affects the remission positively or not: they presumed that the therapeutic response, early partial or complete clinical and oncological remission develops earlier than in patients treated with chemotherapy. "
08/01/1997 - "Reinduction chemotherapy was shown in the 1980s to improve survival in patients who had achieved a complete remission to initial chemotherapy, and a consensus subsequently developed regarding standard induction chemotherapy for patients with small cell lung cancer. "
04/01/1992 - "Critical checking of the radiological diagnosis of "complete remission" and "partial remission" following induction chemotherapy of small-cell lung cancer in the light of postoperative histological examination."
07/01/2006 - "To evaluate the efficacy of curative and palliative radiotherapy in the treatment of extensive stage small cell lung cancer (E-SCLC), and compare therapy effect on survival with or without metastatic disease. "
10/15/1999 - "Although thoracic radiotherapy is considered to be useful for the treatment of patients with small cell lung carcinoma (SCLC), its optimal administration schedule is still controversial. "
10/01/1984 - "The combined chemo-radiotherapy of small cell lung cancer significantly reduced the incidence of relapse and prolonged the disease free interval but did not affect long-term survival."
01/15/1994 - "We conclude that early administration of locoregional radiotherapy in a combined modality treatment is superior to late consolidative locoregional radiotherapy in limited small cell lung cancer."
07/03/2005 - "[The effect of chemo-radiotherapy on the remission and survival in patients with limited stage small cell lung cancer]."
01/01/2000 - "Randomized trials comparing prophylactic cranial irradiation with no prophylactic cranial irradiation in patients with small cell lung cancer in complete remission. "
01/01/2000 - "This study aims to test whether prophylactic cranial irradiation prolongs survival of patients with small cell lung cancer in complete remission. "
08/12/1999 - "We analyzed individual data on 987 patients with small-cell lung cancer in complete remission who took part in seven trials that compared prophylactic cranial irradiation with no prophylactic cranial irradiation. "
12/01/2015 - "The standard therapy for limited disease small cell lung cancer (LD-SCLC) is concurrent chemoradiotherapy and prophylactic cranial irradiation (PCI) for those who achieve complete remission (CR) or good partial response (PR) with initial therapy. "
12/01/2011 - "Prophylactic cranial irradiation (PCI) should now be considered as a part of the standard treatment of patients with small cell lung cancer (SCLC) in complete remission. "
|4.||Combination Drug Therapy (Combination Chemotherapy)
07/01/1991 - "The aim of our study was to evaluate the role of fiberoptic bronchoscopy both in diagnosing patients with small cell lung carcinoma and in assessing complete remission following combination chemotherapy. "
02/01/2004 - "An evidence-based practice guideline was developed to identify the optimal combination chemotherapy regimen, schedule of administration, and duration of therapy for the first-line treatment of adults with limited-stage small-cell lung cancer. "
02/01/1984 - "It is concluded that even though an increase of static and dynamic lung function parameters, including the ventilation of the affected lung, are seen in patients with small cell lung cancer obtaining complete remission during combination chemotherapy, a marked functional decrease of the perfusion and a ventilation-perfusion mismatch remain."
04/01/2001 - "Studies are ongoing to evaluate the efficacy of combination chemotherapy using new agents either together or with other known effective drugs for the treatment of small cell lung cancer. "
01/01/2003 - "Combination chemotherapy has been the mainstay of treatment for extensive stage small cell lung cancer (SCLC) over the last 25 years even though it only gives a short prolongation in median survival time. "
|5.||Heterologous Transplantation (Xenotransplantation)
12/01/2014 - "Thus, we combined AZD3965 with fractionated radiation to treat small cell lung cancer (SCLC) xenografts and showed that the combination provided a significantly greater therapeutic effect than the use of either modality alone. "
09/01/1995 - "We have studied the therapeutic efficacy of 131I-labelled monoclonal antibody 123C3 in human small-cell lung carcinoma xenografts established from the NCI-H69 cell line in nude mice. "
10/01/2003 - "We review our studies using BR96-DOX in a human small-cell lung carcinoma intracerebral xenograft model in nude rats. "
05/01/1988 - "In this study membranes isolated from a human small cell lung cancer xenograft (Mar), that bound [3H]PN200-110, a VGCC antagonist, were subjected to Western blotting using plasma from 12 LEMS patients and eight controls. "
01/01/2015 - "90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer Xenografts."